All the latest news on the marijuana space delivered directly to your inbox.
Read our Medical Marijuana Compound Report for Free Today!
There will be a sudden wave of "Marijuana Millionaires" in 2017 - will you be one?

13x13x1 READ MORE

Emerging Market Report

Biotechs Develop Proprietary Systems to Drive CBD Research and Development

With a market that’s expected to grow from $2 billion in 2020 to $50 billion in only nine years, according to Statista, biotechnology companies are increasingly focused on the development of proprietary systems and procedures to drive research and production of cannabinoid pharmaceuticals.

13x13x1 READ MORE
Why InMed's (CSE: IN; OTCQB: IMLFF) Ground Breaking Biosynthesis Program Adds Investor Value

We think that InMed’s proprietary technology could put $6.6 Billion in play and make it one of the strongest biotech stocks in the market. We also think InMed is in the right place at the right time to create real value for investors in the Industry. Here's a few reasons why.

13x13x1 READ MORE
Canopy Growth increases international footprint by expanding into Jamaican medical market with the introduction of Tweed JA

Canopy Growth Corporation (TSX: WEED) is pleased to announce that it has launched a strategic partnership in the Jamaican cannabis market as part of its ongoing international expansion.

13x13x1 READ MORE
Please see full disclaimers on the website applicable to all content provided by TSI, wherever published or re-published:

This news release/advertorial is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed on this website unless you can afford to lose your entire investment. Also, investing in small-cap and micro-cap securities is highly speculative and carries an extremely high degree of risk. This website makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website. Compensation: A thirty-six-thousand-dollar investor relations budget is being managed by The Seed Investor. Any funds leftover after expenses for research, overhead, advertising and public relations related to InMed Pharmaceuticals Inc. (ticker symbol (CSE: IN; OTCQB: IMLFF) will be considered profit. The Seed Investor and/or entities related to The Seed Investor hold shares in (CSE: IN; OTCQB: IMLFF) and intend to sell those shares. Please review all investment decisions with a licensed inv­estment advisor. 
32x32x1   32x32x2
9375 E Shea Blvd Ste 100
Scottsdale 85260
©2019, All Rights Reserved  |  Unsubscribe   |   View this in Browser

To keep receiving emails from us, please add us to your address book.